Skip to main content

Advertisement

Table 3 Changes in CV risk factors from baseline to last measurement in the pooled cohorts of 8 trials of linagliptin versus total comparators (placebo and active treatment)

From: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

  Pooled linagliptin Pooled total comparators
  Baseline Study end Baseline Study end
HbA1c , mmol/mol 64 ± 10 58 ± 11 63 ± 10 60 ± 13
HbA1c, % 8.1 ± 0.9 7.5 ± 1.0 8.0 ± 0.9 7.7 ± 1.2
Systolic BP, mmHg 131 ± 15 130 ± 15 132 ± 15 132 ± 15
Diastolic BP, mmHg 79 ± 9 78 ± 9 79 ± 9 79 ± 9
Total cholesterol, mmol/L 4.6 ± 0.6 4.6 ± 0.6 4.6 ± 0.6 4.7 ± 0.6
Triglycerides, mmol/L 2.6 ± 1.8 2.5 ± 1.8 2.6 ± 1.9 2.6 ± 1.9
Body weight, kg 78.9 ± 17.7 78.9 ± 17.6 81.0 ± 17.4 81.6 ± 17.9
  1. Values are mean ± SD. BP, blood pressure.